Develpmental Therapeutics

开发治疗计划是卡马诺斯癌症研究所努力开发、了解和测试癌症新疗法的基石。为实现这一目标，该方案参与了针对特定目标的新化合物的合成以及对新确定的化合物的提炼。在我们的第一阶段小组进行测试之前，这些化合物最初是使用体外系统和动物模型进行研究的。我们已经开发了新的试剂和方法，已经进入临床测试。该计划的第二个要素涉及了解和改善肿瘤对化疗和放射治疗的反应的新方法，其中包括药物药效学研究和对 正常组织和肿瘤标本中药物代谢和耐药的途径。该计划的第三个目标是扩大正在开发的新的非侵入性成像方法(例如，PET、MRI、超声波)的使用，以测量肿瘤的生长、灌注和药物动力学。最后，我们正在第二阶段和第二阶段试验中验证我们的新方法。我们的教职员工将这项研究作为研究人员在我们机构发起的试验的一部分，作为多中心研究的一部分，或通过许多合作小组在国家试验中进行。这些主题中的每一个都将临床和基础科学研究人员聚集在一起，以产生创新的新技术 治疗方法和评估方法。乳房、人口研究和预防、分子生物学和人类遗传学以及蛋白质酶和癌症项目的研究人员正在与开发治疗学的同事合作测试新的治疗方法。在过去的几年里，大量新的治疗方法被引入临床，更多的治疗方法仍在酝酿中。该计划的重点是如何加快评估每一种新疗法的前景和缺陷，最终为患者提供最好的生存机会。

The Developmental Therapeutics Program is the keystone of the Karmanos Cancer Institute's effort to develop, understand, and test new treatments for cancer. To achieve this goal the Program is involved in the synthesis of new compounds directed at specific targets as well as the refinement of newly identified compounds. These compounds are initially studied using in vitro systems and animal models prior to testing by our Phase I group. We have developed new agents and approaches that have already entered clinical testing. A second element of the program involves new approaches to understanding and improving tumor response to chemo- and radiotherapy, which includes studies of drug pharmacodynamics and the analysis of pathways of drug metabolism and resistance in normal tissue and tumor samples. The third aim of the program expands the use of new non-invasive imaging approaches (e.g., PET, MRI, ultrasound) that are being developed to measure tumor growth, perfusion, and drug kinetics. Finally, we are validating our new approaches in Phase II and Phase Ill trials. Our faculty conducts this research as part of investigator initiated trials at our institution, as part of multicenter studies, or in national trials through a number of cooperative groups. Each of these main themes brings clinical and basic science researchers together to produce innovative new therapies and means of assessment. Investigators in the Breast, Population Studies and Prevention, Molecular Biology and Human Genetics, and Proteases and Cancer Programs are collaborating in testing new therapeutic approaches along with colleagues in Developmental Therapeutics. Over the last few years a large number of new treatments have been introduced to the clinic, and a larger number are still in the pipeline. This Program is focused on ways to speed the assessment of the promise and pitfalls of each new therapy to ultimately provide patients with the best possible chance at survival.